Tazobactam

證據等級: L5

預測適應症: 2 個

Tazobactam: From Beta-Lactamase Inhibitor to Pneumonia Treatment

One-Sentence Summary

Tazobactam is a β-lactamase inhibitor that is always co-administered with partner β-lactam antibiotics (most notably piperacillin and ceftolozane) to protect them from enzymatic degradation by resistant bacteria; it has no registered standalone indication in the Philippines. The TxGNN model predicts it may be effective for Pneumonia, with 50 clinical trials and 20 publications currently supporting this direction. Evidence quality is exceptionally high, as numerous Phase 3 RCTs have already validated tazobactam-containing combinations (Pip/Taz and Ceftolozane/Taz) as standard-of-care regimens for hospital-acquired and ventilator-associated pneumonia worldwide.

Quick Overview

Item	Content
Original Indication	No standalone registration; used as a β-lactamase inhibitor component in fixed-dose combination antibiotics
Predicted New Indication	Pneumonia (hospital-acquired / ventilator-associated)
TxGNN Prediction Score	99.46%
Evidence Level	L1 (≥2 completed Phase 3 RCTs for tazobactam-containing regimens)
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Tazobactam (DrugBank DB01606) is a penicillanic acid sulfone β-lactamase inhibitor. It does not kill bacteria on its own; instead, it irreversibly binds and inactivates a broad spectrum of β-lactamases — including Ambler class A enzymes such as TEM, SHV, and CTX-M extended-spectrum β-lactamases (ESBLs) — produced by Gram-negative pathogens. By shielding the co-administered β-lactam from hydrolysis, tazobactam restores and amplifies bactericidal activity against organisms that would otherwise be resistant.

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are predominantly caused by Gram-negative pathogens (Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacterales) that frequently produce β-lactamases. The biological rationale for the TxGNN prediction is therefore mechanistically straightforward: by inhibiting the primary resistance mechanism of these organisms, tazobactam enables its partner β-lactam to penetrate and destroy the offending pathogen in the lung. Piperacillin/tazobactam has been a guideline-endorsed empirical option for HAP/VAP for decades, and ceftolozane/tazobactam received FDA approval in 2019 specifically for ventilated nosocomial pneumonia caused by susceptible Gram-negative bacteria, including multidrug-resistant (MDR) Pseudomonas aeruginosa.

The prediction score of 99.46% reflects the TxGNN knowledge graph’s recognition that tazobactam’s molecular interactions in the drug–disease network are tightly linked to respiratory bacterial infections, fully consistent with its real-world clinical trajectory. The absence of a Philippines registration is a market access gap rather than a scientific concern.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02070757	Phase 3	Completed	726	ASPECT-NP pivotal trial: ceftolozane/tazobactam non-inferior to meropenem for Day-28 all-cause mortality in ventilated nosocomial pneumonia (VABP/HABP)
NCT02493764	Phase 3	Completed	537	RESTORE-IMI 2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam in HABP/VABP — confirmed PIP/TAZ as active comparator benchmark
NCT03583333	Phase 3	Completed	274	Multinational RESTORE-IMI 2 China extension: IMI/REL non-inferior to PIP/TAZ for HABP/VABP by Day-28 all-cause mortality
NCT00253955	Phase 3	Completed	460	Levofloxacin 750 mg od vs piperacillin/tazobactam 4 g/500 mg q8h for mild-to-moderate HAP — non-inferiority demonstrated
NCT03581370	Phase 3	Recruiting	80	Pharmacokinetic comparison of 4-hour prolonged vs 1-hour standard infusion of ceftolozane/tazobactam 2 g TID for VAP due to Pseudomonas aeruginosa in ICU
NCT04673175	Phase 4	Terminated	17	Ceftolozane/tazobactam plus rapid molecular diagnostics for MDR Pseudomonas bacteremia/pneumonia in haematological malignancy patients — terminated early due to low enrolment
NCT04223752	Phase 1	Completed	41	PK, safety and tolerability of ceftolozane/tazobactam in paediatric patients with nosocomial pneumonia — supports dose extrapolation to children
NCT04986254	N/A	Completed	179	Multi-centre PK study defining individualised dosing regimens (including piperacillin/tazobactam) to maximise target attainment for ICU pneumonia
NCT03897582	N/A	Recruiting	65	Beta-lactam (including pip/taz) dosing optimisation for ICU pneumonia patients undergoing continuous renal replacement therapy — addresses a critical PK/PD gap
NCT05102162	Phase 4	Terminated	35	Beta-lactam continuous vs intermittent infusion for severe Gram-negative pneumonia (meropenem, cefepime, piperacillin/tazobactam) — assessing bacterial resistance emergence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31563344	2019	RCT (Phase 3)	The Lancet Infectious Diseases	ASPECT-NP: ceftolozane/tazobactam non-inferior to meropenem for Gram-negative nosocomial pneumonia; supports approval for VAP/HABP
32785589	2021	RCT (Phase 3)	Clinical Infectious Diseases	RESTORE-IMI 2: IMI/REL vs PIP/TAZ for HABP/VABP — piperacillin/tazobactam confirmed as valid reference standard with robust clinical data
39674398	2025	RCT (Phase 3)	International Journal of Infectious Diseases	IMI/REL non-inferior to PIP/TAZ in critically ill HABP/VABP patients — further validates pip/taz as guideline comparator
10353303	1999	Review	Drugs	Comprehensive review of piperacillin/tazobactam: established efficacy for lower respiratory tract infections; broad Gram-positive, Gram-negative and anaerobic spectrum
32662691	2020	Review	Expert Review of Anti-infective Therapy	Ceftolozane/tazobactam for HAP: most active anti-pseudomonal agent including MDR/XDR strains; clinical/microbiological success >70–80%
35488823	2022	Review	Revista Española de Quimioterapia	Ceftolozane/tazobactam in nosocomial pneumonia: MIC and MPC values narrow, reducing mutant selection; time-dependent pharmacokinetics favour extended infusion
38823453	2024	Systematic review / Network meta-analysis	Clinical Microbiology and Infection	Optimal empiric antibiotic regimens for non-VAP HAP: piperacillin/tazobactam among the best-supported options across RCTs
38902935	2025	Observational	Clinical Infectious Diseases	Resistance development in MDR Pseudomonas bacteremia/pneumonia: ceftolozane-tazobactam had lower resistance emergence (10%) vs ceftazidime-avibactam (40%)
38936906	2024	Clinical study	In Vivo	Prophylactic mini-tracheostomy plus perioperative tazobactam/piperacillin significantly reduced pneumonia incidence in high-risk post-oesophagectomy patients
34158237	2021	Retrospective cohort (PSM)	Journal of Infection and Chemotherapy	Aspiration pneumonia: ceftriaxone comparable to piperacillin/tazobactam or carbapenems — useful for de-escalation strategy context

Philippines Market Information

Tazobactam has no registered products with the Philippine FDA (FDA-Philippines). There are 0 active licenses on record. Any clinical use in the Philippines would require formal registration of a tazobactam-containing combination product (e.g., piperacillin/tazobactam or ceftolozane/tazobactam) before deployment.

Safety Considerations

Full safety data (key warnings, contraindications, drug interactions) was not retrievable from the current data sources for this Evidence Pack. The DDI query returned no results, and FDA-Philippines package insert data was not available.

Based on general knowledge of tazobactam-containing combinations from global regulatory approvals:

Tazobactam is generally well tolerated; adverse events are primarily attributable to the partner β-lactam.
Common reactions with piperacillin/tazobactam include diarrhoea, nausea, skin rash, and elevated liver enzymes.
Risk of Clostridioides difficile-associated disease exists, as with all broad-spectrum antibiotics.
Renal dose adjustment is required for combinations (e.g., ceftolozane/tazobactam carries a warning for reduced efficacy in patients with creatinine clearance 30–50 mL/min due to acute kidney injury).

Please refer to the current package insert of the relevant tazobactam-containing combination product for full prescribing information, warnings and contraindications.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction for tazobactam in pneumonia is supported by the highest level of clinical evidence (L1): multiple completed Phase 3 RCTs have established tazobactam-containing combinations (piperacillin/tazobactam and ceftolozane/tazobactam) as standard-of-care reference arms or approved treatments for hospital-acquired and ventilator-associated bacterial pneumonia globally. The prediction reflects a mechanistically sound and clinically validated indication. The principal barrier to use in the Philippines is a registration gap, not a scientific one.

To proceed, the following is needed:

Philippines FDA registration of a tazobactam-containing fixed-dose combination product (priority: piperacillin/tazobactam 4.5 g IV, and/or ceftolozane/tazobactam 1.5 g IV) via the FDA-Philippines Center for Drug Regulation and Research (CDRR)
Local package insert and prescribing information for any combination product registered, including Filipino-language patient information if required
Mechanism of action documentation (DrugBank API query for DB01606) to complete the pharmacological profile and support educational materials for Philippine prescribers
Safety monitoring plan covering renal function monitoring (dose adjustment for CrCl < 50 mL/min), hepatic enzyme surveillance, and C. difficile surveillance protocols
Antimicrobial stewardship framework for deployment in Philippine ICU/hospital settings, given the risk of selecting for carbapenem-resistant organisms if piperacillin/tazobactam is over-used in ESBL infections (per the MERINO trial signal, PMID 30208454)
Local resistance surveillance data (Philippine antimicrobial resistance data from the Antimicrobial Resistance Surveillance Program, ARSP) to confirm that target pathogens in Philippine HAP/VAP remain susceptible to tazobactam-containing regimens
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.